Osivax

Fundraising by biopharmaceutical companies surged in 2024 to $86.67bn, up 16.2% from $74.59bn in 2023, according to data collected by Biomedtracker. The good fortune was shared across both public and

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Boehringer Ingelheim GmbH is closely

Germany’s BI Licenses Tumor-Specific Antibodies From Singapore Lab Boehringer Ingelheim GmbH and Singapore’s Agency for Science, Technology and Research (A*STAR) unveiled a global licensing agreem

It appears that the biopharmaceutical industry is on its way to not only beat but completely demolish prior venture capital fundraising records, based on totals for the first half of 2020 reported in